MedTrace Logo

Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention

NCT03613337 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2020-03-03

No results posted yet for this study

Summary

Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified.

Smoking is one of most important factors, however the results were contradictory. And the genetic factors of restenosis have been studied mostly in European populations. Based on literature review, study of candidate genes for restenosis in Chinese population was insufficient.

With due attention to this matter mentioned above, the investigators aim to preliminary explore genetic variation and smoking effect on clinical restenosis in patients diagnosed with after percutaneous coronary intervention in the Chinese population, with correlation analysis of factors and gene-set analysis of biological pathways related to restenosis and platelet approach were widely used in this study.

Conditions

  • Smoking Status
  • Genetic Risk Factors
  • Restenosis
  • Clopidogrel
  • Coronary Heart Disease
  • Percutaneous Coronary Intervention

Interventions

OTHER

clinical restenosis

The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.

Sponsors & Collaborators

  • Cui Yimin

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2020-07-31
Completion
2020-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613337 on ClinicalTrials.gov